Associated Genetic Biomarkers
Associated Diseases
Associated Pathways


Location [1]
MAP kinase signaling
Protein [2]
GTPase NRas
Synonyms [1]

NRAS (neuroblastoma RAS viral (v-ras) oncogene homolog) encodes for the GTPase NRas protein, one of three human RAS proteins. RAS proteins are small GTPases that are central mediators downstream of growth factor receptor signaling and therefore critical for cell proliferation, survival, and differentiation. NRAS is implicated in the pathogenesis of several cancers (for review see PMID: 17384584).

NRAS is altered in 3.03% of all cancers with cutaneous melanoma, melanoma, colon adenocarcinoma, acute myeloid leukemia, and lung adenocarcinoma having the greatest prevalence of alterations [3].

NRAS GENIE Cases - Top Diseases

The most common alterations in NRAS are NRAS Mutation (2.87%), NRAS Exon 3 Mutation (1.90%), NRAS Exon 3 Missense (1.88%), NRAS Codon 61 Missense (1.72%), and NRAS Exon 2 Mutation (0.95%) [3].

NRAS GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of NRAS in Diseases

Melanoma +

Malignant Solid Tumor +

Colorectal Carcinoma +

Non-Small Cell Lung Carcinoma +

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Chronic Myelomonocytic Leukemia +

Colorectal Adenocarcinoma +

Multiple Myeloma +

Non-Hodgkin Lymphoma +

Pancreatic Carcinoma +

Cutaneous Melanoma +

Ovarian Carcinoma +

Pancreatic Ductal Adenocarcinoma +

Acute Lymphoblastic Leukemia +

Thyroid Gland Carcinoma +

Cancer +

Glioma +

Neurofibromatosis Type 1 +

Poorly Differentiated Thyroid Gland Carcinoma +

Secondary Acute Myeloid Leukemia +

Therapy-Related Acute Myeloid Leukemia +

Myelodysplastic Syndrome With Excess Blasts-2 +

Juvenile Myelomonocytic Leukemia +

Histiocytic And Dendritic Cell Neoplasm +

Head And Neck Squamous Cell Carcinoma +

Small Cell Lung Carcinoma +

Low Grade Glioma +

Squamous Cell Lung Carcinoma +

Breast Carcinoma +

Chronic Myelomonocytic Leukemia-2 +

Chronic Myelomonocytic Leukemia-0 +

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +

Embryonal Rhabdomyosarcoma +

Thyroid Gland Follicular Carcinoma +

T-Cell Acute Lymphoblastic Leukemia +

Mucosal Melanoma +

Chronic Myelomonocytic Leukemia-1 +

Low Grade Ovarian Serous Adenocarcinoma +

Thyroid Gland Papillary Carcinoma +

Refractory Anemia With Excess Blasts +

Myeloid Neoplasm +

Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +

Rectal Carcinoma +

Colon Carcinoma +

Malignant Peripheral Nerve Sheath Tumor +

Cholangiocarcinoma +

Endometrial Carcinoma +

Mantle Cell Lymphoma +

Secondary Myelodysplastic Syndrome +

Therapy-Related Myelodysplastic Syndrome +

Lymphoma +

Neuronal And Mixed Neuronal-Glial Tumors +

Ganglioglioma +

Soft Tissue Sarcoma +

Bladder Carcinoma +

Esophageal Carcinoma +

Sarcoma +

Thymic Carcinoma +

Lung Adenocarcinoma +

Lung Carcinoma +

Uveal Melanoma +

Head And Neck Carcinoma +

Diffuse Glioma +

Squamous Cell Carcinoma +

Chronic Myeloid Leukemia +

Adenocarcinoma Of The Gastroesophageal Junction +

Glioblastoma +

Neuroblastoma +

Astrocytic Tumor +

Hepatocellular Carcinoma +

Pancreatic Adenocarcinoma +

Diffuse Large B-Cell Lymphoma +

Anaplastic Astrocytoma +

Gastric Adenocarcinoma +

Gastric Carcinoma +

Prostate Carcinoma +

Renal Cell Carcinoma +

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +

B-Cell Acute Lymphoblastic Leukemia +

Double-Hit Lymphoma +

Dysembryoplastic Neuroepithelial Tumor +

Gangliocytoma +

Low-Grade Neuroepithelial Tumor, NOS +

Peripheral T-Cell Lymphoma +

Pilocytic Astrocytoma +

Pilomyxoid Astrocytoma +

Rhabdoid Tumor +

Schwannoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015.

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.